OliPass

OliPass EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of OliPass (244460.KQ) as of Oct 22, 2026 is -1.31. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -0.91 — a change of 43.36% (lower).

EV/FCF

-1.31

YoY

43.36%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of OliPass is 2024 -1.31 . EV/FCF (Enterprise Value to Free Cash Flow) of OliPass was 2023 -0.91 . It decreases by 43.36% lower compared to the previous year.

The OliPass EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-0.39 KRW
Jan 1, 2018
-1.52 KRW
Jan 1, 2019
0.81 KRW
Jan 1, 2020
1.39 KRW
Jan 1, 2021
0.68 KRW
Jan 1, 2022
-0.05 KRW
Jan 1, 2023
-0.91 KRW
Jan 1, 2024
-1.31 KRW
The OliPass EV/FCF history
YEAREV/FCFYoY
-1.31+43.36%
-0.91+1,617.22%
-0.05-107.79%
0.68-50.98%
1.39+72.92%
0.81-153.20%
-1.52+287.73%
-0.39+330.22%
-0.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OliPass Stock analysis

What does OliPass do? OliPass Corp develops and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, and cancer immunotherapy medicine. The company also researches, develops, and sells functional cosmetics using artificial gene platform technology. Its primary customers are healthcare providers and pharmaceutical companies seeking innovative treatments and cosmetic solutions. OliPass Corp generates revenue through the sale of these medical products and functional cosmetics, focusing on biotechnology-driven healthcare and beauty markets. The company's product portfolio includes nonopioid analgesics for pain management, hyperlipidemia medicines for cholesterol control, ocular angiogenesis inhibitors for eye conditions, duchenne dystrophy treatments, and cancer immunotherapy medicines. Functional cosmetics developed via artificial gene platform technology target consumers interested in advanced skincare. OliPass Corp's revenue streams are derived from direct sales to healthcare institutions and pharmaceutical distributors, with a strong emphasis on biotech innovation in both medicine and cosmetics. OliPass Corp's business model centers on developing proprietary biological products through research and development. The firm sells its medicines and functional cosmetics to healthcare providers and pharmaceutical companies, leveraging its artificial gene platform technology for product differentiation. Revenue is generated through the commercialization of its medical and cosmetic product lines, which cater to specific health and beauty segments requiring advanced biotechnological solutions. OliPass is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OliPass stock

EV/FCF (Enterprise Value to Free Cash Flow) of OliPass is -1.31 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of OliPass changed from -0.91 to -1.31, representing a 43.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) OliPass since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s OliPass with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — OliPass

All Key Metrics — OliPass